Pharmafile Logo
Pharmafocus logo
Advanced Search

Almirall and Forest’s phase III COPD drug misses goal

November 3, 2010
Research and Development Aclidinium bromide, Almirall, COPY, Forest, Forest Laboratories, chronic obstructive pulmonary disease

Almirall and Forest’s COPD drug aclidinium bromide has disappointed in a phase III trial by producing fewer benefits than found …

News

Pfizer Q3 profits hit hard

November 3, 2010
Sales and Marketing Liptior sales, Pfizer, Pfzier Q3 results, Wyeth

The integration of Wyeth into Pfizer continues to drive its revenue growth, but at a cost – charges from the …

News

Lonza says contract manufacturing business is recovering

November 2, 2010
Manufacturing and Production API, Lonza, contract manufacturing, pharma manufacturing

Lonza said its contract manufacturing business seems to be enjoying a return to form in the third quarter, despite continued …

News

Pfizer pulls more Lipitor over odour problem

November 2, 2010
Manufacturing and Production Lipitor, Lipitor recall, Pfizer, manufacturing compliance, recalls

Pfizer has widened its Lipitor recall after yet another incident in which consumers reported a musty smell emanating from bottles …

News
Lilly scientists

Lilly to open diabetes research centre in China

November 2, 2010
Research and Development China, Eli Lilly & Co, Lilly Research Laboratories in China, diabetes, lilly

The march of foreign pharma companies into China is to continue with Eli Lilly and Co’s opening of a diabetes …

News

Nycomed expands China presence with Techpool stake

November 2, 2010
Research and Development, Sales and Marketing China, Guangdong Techpool biopharma, Nycomed, emerging markets, emerging pharma markets

Swiss-based Nycomed has acquired a majority stake in Guangdong Techpool biopharma in China, extending its presence in the top tier …

News

BMS faces approval block unless GMP issues are resolved

November 2, 2010
Manufacturing and Production BMS, Bristol-Myers Squibb, FDA, Puerto Rico, belatacept, manufacturing compliance, pharma manufacturing

Bristol-Myers Squibb has been threatened with a block on approvals of certain new drugs, including a biologic for preventing organ …

News

Lundbeck UK appoints senior management team

November 2, 2010
Research and Development, Sales and Marketing Amanda Badrick, Andy Davis, Andy Jones, Helen Carberry, Lundbeck, Steve Ferguson, appointment, recruitment, research and development, sales and marketing

Lundbeck UK has formed a new senior management team, appointing Steve Ferguson, Andy Davis, Andy Jones, Helen Carberry and Amanda …

News

Abbott hep C drug ABT-450/r impresses in mid-stage trial

November 2, 2010
Research and Development ABT-450/r, Abbott, Abbott Laboratories, American Liver Disease congress, Enanta Pharmaceuticals, Norvir, hepatitis C

Mid-stage trial results of Abbott Laboratories’ oral hepatitis C drug ABT-450/r have impressed at the American Liver Disease congress. The …

News

Regulators must catch up with medical science, says FDA

November 2, 2010
Research and Development, Sales and Marketing Advancing Regulatory Science, Critical Path Initiative’, Dr Margaret Hamburg, FDA, regulatory affairs

The head of the FDA has declared a need for ‘regulatory science’ to catch up with the advances in medical …

News

6 tips for regulatory compliance in logistics

November 2, 2010
Manufacturing and Production, Research and Development Biocair, GMP, International Council for Harmonisation, pharma logistics, regulatory compliance

Regulation! Regulation! Regulation! Never has our business been more highly regulated than it is today. Seemingly, rules change every day. …

Feature

‘Therapeutic clusters’ collaboration launched

November 2, 2010
Research and Development ABPI, BIA, Immunology Initiative, Medical Research Council, Office for Strategic Co-ordination of Health and Research, Therapeutic Capability Clusters’, UCB, therapeutic clusters

Two initiatives linking the pharma industry and government-funded research and academia are to go ahead, with the aim of reviving …

News

Relief as life sciences spared in UK cutbacks

November 1, 2010
Research and Development ABPI, Comprehensive Spending Review, Diamond Synchrotron, UK Centre for Medical Research Innovation, UKCMRI, government, science funding

UK government funding for life sciences R&D has been spared from the deep cuts some had feared. Many in the …

News

FDA approves Novartis’ Afinitor

November 1, 2010
Sales and Marketing Afinitor, Novartis, subependymal giant cell astrocytomas, tuberous sclerosis

Novartis’ drug Afinitor has been approved by US authorities as a first line treatment for patients with benign brain tumours …

News

TranslateMedia ranked 4th in UK Deloitte Technology Fast 50 for 2010

November 1, 2010
Business Services

 TranslateMedia announced today that it has been ranked 4th in this year’s UK Deloitte Technology Fast 50. The Technology Fast …

News
Press release

Pfizer to seek US approval for crizotinib next year

November 1, 2010
Research and Development, Sales and Marketing FDA submission, NSCLC, Pfizer, crizotinib, lung cancer, non-small cell lung cancer

Pfizer will submit its lung cancer candidate crizotinib to the FDA for US approval in the first half of next …

News

German rebates to cost pharma 1 billion euro

November 1, 2010
Sales and Marketing BPI, German pharma market, Germany, Gesetzliche Krankenversicherung, healthcare costs

The pharma industry will contribute over 1 billion euro ($1.4 billion) to Germany’s cost-containment efforts by the end of 2010. …

News

GSK signs rare diseases deal with Amicus

November 1, 2010
Research and Development, Sales and Marketing Amicus Therapeutics, Fabrazyme, Fabry disease, GSK, GlaxoSmithKline, pharmacological chaperones

GlaxoSmithKline is partnering with US biopharmaceutical company Amicus Therapeutics to develop and commercialise its late-stage Fabry disease drug Amigal. GSK …

News

Cross-functional marketing leadership

November 1, 2010
Sales and Marketing Nikki Atkins, WG Consulting Healthcare, leadership, marketing strategies, pharma marketing

Building a multi-disciplinary team across a pharma company is a tough challenge – but the demands of the modern development …

Feature
AstraZeneca

Patent expiries bite into AstraZeneca revenues

October 29, 2010
Sales and Marketing AstraZeneca, Crestor, Q3, Seroquel

Generic competition and a major drop off in pandemic influenza products saw AstraZeneca’s revenue fall for the third quarter. Revenue …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026